Academic Journal
أعرض في EDS

Unique fusion is associated with marked response to crizotinib in lung adenocarcinoma

التفاصيل البيبلوغرافية
العنوان: Unique fusion is associated with marked response to crizotinib in lung adenocarcinoma
المؤلفون: Maurício Fernando Silva Almeida Ribeiro, Luiza Lara Gadotti, Karina Perez Sacardo, Carlos Diego Holanda Lopes, Rodrigo Saddi, João Victor Machado Alessi, Mariana Petaccia de Macedo, Ellen Caroline Toledo do Nascimento, Leonardo de Abreu Testagrossa, Artur Katz
المصدر: SAGE Open Medical Case Reports, Vol 10 (2022)
بيانات النشر: SAGE Publishing, 2022.
سنة النشر: 2022
المجموعة: LCC:Medicine (General)
مصطلحات موضوعية: Medicine (General), R5-920
الوصف: Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1 ) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partners on tyrosine kinase inhibitor efficacy. We herein describe a case of a 26-year-old never-smoker patient from southern Africa with metastatic lung adenocarcinoma driven by SLC12A2 - ROS1 fusion, who had a pronounced and durable response to crizotinib. The present case underscores the importance of pursuing actionable alterations in patients with similar clinical and epidemiological characteristics. In addition, provides the second report of crizotinib activity against lung malignancies harboring the unique SLC12A2-ROS1 fusion and highlights the importance of a deeper understanding of molecular alterations in underrepresented subgroups of patients to tailor the decision-making in daily practice.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2050-313X
2050313X
Relation: https://doaj.org/toc/2050-313X
DOI: 10.1177/2050313X221100407
URL الوصول: https://doaj.org/article/28466b5038404de88eabd4d79f59b59e
رقم الانضمام: edsdoj.28466b5038404de88eabd4d79f59b59e
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2050313X
DOI:10.1177/2050313X221100407